The resulting imprinted cavities can be used to identify the corresponding proteins, thereby enabling MIP-NPs to actively target HER2-positive breast cancer cells, effectively targeting and recognizing cancer cells and releasing drugs to kill the breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.